Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK3207 · 2 trials · 2 indications
Reduction of a Grade 2 or 3 severity migraine at baseline to Grade 0 at 2 hours postdose. Rating of Headache Severity (Scale from Grade 0 to 3): * Grade 0: No pain * Grade 1: Mild pain * Grade 2: Moderate pain * Grade 3: Severe pain
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | MK3207- 2.5 mg |
| 2 | EXPERIMENTAL | MK3207- 5 mg |
| 3 | EXPERIMENTAL | MK3207- 10 mg |
| 4 | EXPERIMENTAL | MK3207- 20 mg |
| 5 | EXPERIMENTAL | MK3207- 50 mg |
| 6 | EXPERIMENTAL | MK3207- 100 mg |
| 7 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| MK3207- 2.5 mg | DRUG | Arm 1: MK3207 2.5 mg taken after migraine onset. |
| MK3207- 5 mg | DRUG | Arm 2: MK3207 5 mg taken after migraine onset. |
| MK3207- 10 mg | DRUG | Arm 3: MK3207 10 mg taken after migraine onset. |
| MK3207- 20 mg | DRUG | Arm 4: MK3207 20 mg taken after migraine onset. |
| MK3207- 50 mg | DRUG | Arm 5: MK3207 50 mg taken after migraine onset. |
| MK3207- 100 mg | DRUG | Arm 6: MK3207 100 mg taken after migraine onset. |
| Comparator: placebo (unspecified) | DRUG | Placebo taken after migraine onset. |
| MK3207 | DRUG | M3207 (20 mg); patients will be administered a single dose of 100 mg of MK3207 (i.e., 5 x20-mg tablets). |
Inclusion Criteria: * Men and Women from 18 to 65 years of age * 1+ year history of migraine that typically last from 4 to 72 hours if untreated * Had from 2 to 8 moderate or severe migraine attacks per month in the last 2 months * Not pregnant or planning to become pregnant in next 6 months Exclu...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 13 | PHASE3 | Atogepant |
| Pfizer Inc. | PFE | 9 | PHASE3 | Rimegepant |
| Eli Lilly and Company | LLY | 2 | PHASE3 | Galcanezumab |
| Amgen Inc. | AMGN | 2 | PHASE3 | Erenumab Dose 1 |
| Ki Health Partners. LLC | RVNC | 1 | - | Daxibotulinumtonix A |
MK3207 is an investigational small molecule being developed for the treatment of migraine and migraine disorders. It has been studied in clinical trials for acute migraine treatment. The drug is not approved and remains in clinical development.
MK3207 is a small molecule designed to act on targets relevant to migraine. It has been evaluated in clinical trials for its effects on migraine symptoms. The specific molecular target is not disclosed in the available information.
MK3207 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The drug is currently in clinical development for migraine.
MK3207 is in Phase 2 clinical development. It has completed a Phase 2 trial for the treatment of acute migraines, along with a Phase 1 study. The drug is investigational and has not been approved by regulatory authorities.
MK3207 has been studied in two completed clinical trials. NCT00548353 was a Phase 1 study of gastric delay in migraine patients with 22 participants. NCT00712725 was a Phase 2 trial for acute migraine treatment with 676 participants, which was randomized, double-blind, and placebo-controlled.
MK3207 is a distinct investigational compound developed by Merck. It is not known to be the same as any other marketed migraine medication. Its development history includes trials specifically designed to assess its efficacy and safety in migraine patients.